For example, the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study investigated whether treatment with canakinumab, a monoclonal antibody that specifically neutralises IL-1b, would benefit people with CRP > 2.0 mg/L and a history of myocardial infarction [6]. This evidence concerns the gene CRP and myocardial infarction.